Eli Lilly and Co (LLY) : Senzar Asset Management added new position in Eli Lilly and Co during the most recent quarter end. The investment management firm now holds 601,800 shares of Eli Lilly and Co which is valued at $48,276,396 , the company said in a statement filed on Aug 12, 2016 with the SEC.Eli Lilly and Co makes up approximately 9.60% of Senzar Asset Management’s portfolio.
Other Hedge Funds, Including , Valley National Advisers Inc boosted its stake in LLY in the latest quarter, The investment management firm added 1,600 additional shares and now holds a total of 17,159 shares of Eli Lilly and Co which is valued at $1,376,495. Eli Lilly and Co makes up approx 0.69% of Valley National Advisers Inc’s portfolio.Lvw Advisors reduced its stake in LLY by selling 1,304 shares or 24.93% in the most recent quarter. The Hedge Fund company now holds 3,927 shares of LLY which is valued at $315,024. Eli Lilly and Co makes up approx 0.11% of Lvw Advisors’s portfolio.Wms Partners reduced its stake in LLY by selling 816 shares or 14.38% in the most recent quarter. The Hedge Fund company now holds 4,859 shares of LLY which is valued at $389,789. Eli Lilly and Co makes up approx 0.05% of Wms Partners’s portfolio.American Century Companies Inc reduced its stake in LLY by selling 130,210 shares or 14.89% in the most recent quarter. The Hedge Fund company now holds 744,176 shares of LLY which is valued at $62,064,278. Eli Lilly and Co makes up approx 0.07% of American Century Companies Inc’s portfolio.Joel Isaacson boosted its stake in LLY in the latest quarter, The investment management firm added 600 additional shares and now holds a total of 3,868 shares of Eli Lilly and Co which is valued at $315,590. Eli Lilly and Co makes up approx 0.07% of Joel Isaacson’s portfolio.
Eli Lilly and Co opened for trading at $78.33 and hit $78.74 on the upside on Monday, eventually ending the session at $78.6, with a gain of 0.46% or 0.36 points. The heightened volatility saw the trading volume jump to 22,03,303 shares. Company has a market cap of $86,762 M.
On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.